
    
      This Phase 2b, open-label, single-arm, multi-center study will assess the efficacy and safety
      of adavosertib in eligible subjects with histologically confirmed recurrent or persistent
      USC, evidence of measurable disease as per Response Evaluation Criteria in Solid
      Tumors.(RECIST) v1.1, and who have received at least 1 prior platinum-based chemotherapy
      regimen for the management of USC. Subjects with carcinosarcomas are not eligible.
    
  